Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pseudomonas aeruginosa bacteriophage
- Development stage
- Unknown
- Lead developer
- Children's Hospital at Westmead
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Inhalation
01
Overview
Pseudomonas aeruginosa bacteriophage is an investigational biologic (phage therapy) being developed by the Respiratory Department at The Children's Hospital at Westmead, Australia, in collaboration with the Westmead Institute of Medical Research. This personalized medicine approach utilizes obligate lytic bacteriophages specifically selected to target and lyse a patient's individual *Pseudomonas aeruginosa* sputum isolates. It is currently being evaluated in a Phase 1 clinical trial for the treatment of chronic *Pseudomonas aeruginosa* lung infections in children and adolescents with cystic fibrosis, non-CF bronchiectasis, and chronic suppurative lung disease. The therapy is administered via both intrabronchial instillation and nebulisation to ensure direct delivery to the site of infection.
- Other names
- phage therapybacteriophage therapy
02
Targets
P. aeruginosa (Pseudomonas aeruginosa)
Beyond the preview
Go deeper on Pseudomonas aeruginosa bacteriophage.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pseudomonas aeruginosa bacteriophage.